Supriya Lifescience Limited · NSE:SUPRIYA
Supriya Lifescience — Q3 FY2022 Earnings Presentation
37 slides from Supriya Lifescience's earnings presentation, Jan 21, 2022
Slide 1: Supriya Lifescience Ltd. - Investor Presentation Filing
SUPRIYA LIFESCIENCE LTD. Creating true values that bind global health Date: January 21, 2022 To, The Corporate Services Department, Manager - Listing Department Bombay Stock Exchange Limited The National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, D
Slide 2: Investor Presentation Q3 FY2022
Investor Presentation Q3 FY2022 January 2022
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any se
Slide 4: Q3 FY22 Consolidated Financial Performance
Q3 FY22 Consolidated Financial Performance (in INR mn) Revenues Total Income (Rs. Crs) Gross Profit Total Income EBITDA Rs. 1,224.4 Mn Rs. 438.2 Mn Y-o-Y Y-o-Y +44% +54% +44% +45% 1,224.4 806.5 850.2 522.7 PAT Margins Profit After Tax Q3 FY22 Rs. 396.4 Mn Y-o-Y 32% +153% Q3FY21 Q3FY22 Q3FY21 Q3FY22
Slide 5: Q3 & 9M FY22 Consolidated Profit & Loss Statement
Q3 & 9M FY22 Consolidated Profit & Loss Statement (in INR mn) Particulars Q3 FY22 Q3 FY21 Y-o-Y Q2 FY22 Q-o-Q 9M FY22 9M FY21 Y-o-Y Total Revenue 1,224.4 850.2 44% 1,511.8 -19% 3,525.0 2,663.2 32% Cost of Materials Consumed 722.3 422.0 71% 464.4 56% 1,605.9 990.8 62% Changes in Inventories of Finish
Slide 6: Business Mix Revenue Contribution
Business Mix Revenue Contribution (in INR mn) +36% By Region 312.5 229.3 2% 2% 6% 1% 2% 5% 27% 0% 9% 12% India Sales 28% 26% 9% Q3 FY21 Q3 FY22 Q3FY21 49% Q3FY22 1% +48% 857.4 22% 577.5 53% 73% 2% International Sales 72% AFRICA LATIN AMERICA ASIA MIDDLE EAST Q3 FY21 Q3 FY22 CIS NORTH AMERICA EUROPE
Slide 7: Business Mix Revenue Contribution by Therapy
Business Mix Revenue Contribution (in INR mn) Performance of the therapeutic areas in Q3 FY22 By Therapy 6% 2% 7% 9% 1% 27% 8% Q3 FY21 Q3 FY22 11% 8% 62% Q3FY21 Q3FY22 11% 12% 62% 0% 19% 0% 17% 27% Analgesic/anesthetic Anti-malarial Anti-hypertensive Anti-histamine Anti-asthmatic Others 19% 17% Vita
Slide 8: CMD's Message
CMD’s Message “I would like to thank everyone for the overwhelming support we have received for our IPO . With this support and trust from the investors our IPO was oversubscribed by 71.47 times. The company has shown consistent performance for 9 months FY22 with a total revenue of Rs 3,525.0 Mn wit
Slide 9: Agenda
Company Overview Key Strengths Company Strategies Financials 8
Slide 10: Company Overview
Company Overview 9
Slide 11: Journey so far
Journey so far Incorporation & conversion CEP granted for Brompheniramine CEP granted for Pentoxifylline and from a partnership firm to a CEP granted for Maleate, Mepyramine Maleate & Esketamine Hydrochloride; public limited company Chlorphenamine Maleate COFEPRIS and KFDA EUGMP and EDQM Ketamine Hy
Slide 12: Company Overview
Company Overview Well established presence in the API manufacturing, with focus on high value products with limited competition Niche product basket of 38 APIs across diverse therapeutic segments1 Largest exporter of Chlorpeniramine Maleate and Ketamine Hydrochloride from India, contributing to 45~5
Slide 13: Niche Product Portfolio
Niche Product Portfolio Product Therapeutic area Certifications Chlorpheniramine Maleate (CPM) Antihistamine EDQM Approval, US DMF, CEP, Health Canada, Taiwan FDA, NMPA DMF, EDMF Brompheniramine Maleate (BPM) Antihistamine US DMF, NMPA DMF, CEP, EDMF Pheniramine Maleate Antihistamine US DMF, CEP, ED
Slide 14: Key Strengths
Key Strengths 13
Slide 15: Company differentiators
Company differentiators Significant scale with leadership position across key & niche products Backward integrated business model Geographically diversified revenues with a global presence across 86 countries Advanced manufacturing and research and development capabilities Experienced senior managem
Slide 16: Significant scale with leadership position in key products
Significant scale with leadership position in key products Niche product offerings of 38 APIs with demonstrated ability to develop & scale-up production1 Leading exporter from India Presence for 10+ yrs in large & growing markets % share of exports from India (in terms of volume) Cetirizine Dihydroc
Slide 17: Diverse therapeutic segments
… in diverse therapeutic segments % Therapy wise revenue contribution FY19 FY20 FY21 H1FY22 1% 1% 1% 1% 1% 1% 1% 1% 1% 3% 2% 0% 3% 3% 0% 2% 0% 0% 0% 0% 5% 6% 5% 6% 27% 7% 8% 8% 6% 30% 31% 29% 7% 9% 8% 10% 15% 22% 20% 14% 24% 25% 27% 29% Analgesic/antipyretic/anesthetic Anti-allergic Anti-asthma Anti
Slide 18: Strong pipeline focused on further diversification
… and, strong pipeline focused on further diversification DECONGESTANT Dextromethorphan Hydrobromide 1,406 MT EDMF US DMF DECONGESTANT Phenylephrine Hydrochloride 430 MT XANTHINE DERIVATIVES Pentoxifylline 3,798 MT EDMF US DMF CEP ANTIGOUT Allopurinol 1,871 MT ANALGESIC/ ANTI-PYRETIC/ ANAESTHETIC (S
Slide 19: Backward integrated business model
Backward integrated business model Supply Low In-house Cost-competitive Security Price risk Processes Structure Steady supply of Protection against Lesser dependence on Increasing essential raw materials market fluctuations external parties margins A total of 12 products are backward integrated* 01
Slide 20: Diversified revenues with extensive global presence
Diversified revenues with extensive global presence Significant export presence, with low dependence on a specific geography and, balanced mix of presence in regulated & semi/ non-regulated markets Middle Export sales, as a % of revenue from operations Africa North 2% East America 4% 77.0% 76.5% Ind
Slide 21: Advanced manufacturing and R&D capabilities (1/2)
Advanced manufacturing and R&D capabilities (1/2) 4 7 547 KL/day 23,806 sq.mt. Manufacturing blocks Clean Reactor Land segregated therapy wise rooms capacity area ✓ Well delineated areas for R&D, quality control (chemical microbiology), quality assurance, dedicated areas for engineering maintenance,
Slide 22: Advanced manufacturing and R&D capabilities (2/2)
Advanced manufacturing and R&D capabilities (2/2) Focus on uniform manufacturing standards to achieve standardised product quality across markets Ability to handle complex chemistries … … across varied class of reactions Simple to highly complex chiral centre molecules Fridel craft acylation Bromina
Slide 23: Eminent Board of Directors (1/2)
Eminent Board of Directors (1/2) Balasaheb Satish Wagh Smita Wagh Saloni Wagh Shivani Wagh Gulabrao Sawant Chairman & MD Whole-time Director Whole-time Director Whole-time Director Whole-time Director • B.Sc. from R.D National College and • B.A. from Smt. B.M.R. Mahila • B.Sc. from Parle Tilak Vidhy
Slide 24: Eminent Board of Directors (2/2)
Eminent Board of Directors (2/2) Kedar Shankar Bhairav Manojbhai Dileep Kumar Dinesh Navnitlal Neelam Yashpal Karmakar Chokshi Jain Modi Arora Independent Director Independent Director Independent Director Independent Director Independent Director • B.Sc. from the Parle College, • B.Com. from Shri S
Slide 25: Experienced Senior Management
Experienced Senior Management Shireesh Ambhaikar Ashish Nayak Sushanta Mishra Chief Executive Officer Chief Financial Officer Chief Scientific Officer • Bachelor’s, Master’sand PhD in Science from University of Mumbai • He has cleared the final examination held by the ICAI • M.Sc. From Sambalpur Uni
Slide 26: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance Robust revenue growth1 … with increasing gross margins2 … and, focus on profitability (INR mn) (INR mn) +17.7% 3,962.2 66.8% 65.0% 1,782 3,525.0 +56.5% 3,227.1 55.6% 1,425 2,858.6 47.1% 1,238 1,095 1,056 728 734 394 FY19 FY20 FY21 9MFY22 FY19 FY20 FY21 9MFY2
Slide 27: Company Strategies
Company Strategies 26
Slide 28: Company Strategies
Company Strategies Expansion of Expanding product manufacturing portfolio with capabilities increasing R&D capabilities Increase current Continue to focus market presence on operational and enter new excellence markets 27
Slide 29: Expansion of manufacturing capabilities
1 Expansion of manufacturing capabilities Enhancement of KSM manufacturing capabilities Scaling-up contract & support backward integration manufacturing capabilities • Enhance production capacity through capex in existing • Proven expertise in chemical process development & manufacturing sites manuf
Slide 30: Expanding product portfolio with increasing R&D capabilities
2 Expanding product portfolio with increasing R&D capabilities Development of innovative APIs Consolidating market position • Capturing high-value first-to-market opportunities in key Launch of new products … international markets • Dextromethorphan Hydrobromide (decongestant), • Expand into niche t
Slide 31: Increase market presence; focus on operational excellence
3 Increase current market presence & enter new markets • Grow sales & market share in the existing geographies through calculated product launches & by leveraging existing relationships with customers • Focused growth strategy as per applicable regulatory requirements, competition and pricing • Enga
Slide 32: Financial Statements
Financial Statements 31
Slide 33: Summary Statement of Profit and Loss
Summary Statement of Profit and Loss (in INR mn) Particulars 9M FY22 FY21 FY20 FY19 Total Revenue 3,525.0 3,962.2 3,227.1 2,858.6 Cost of Materials Consumed 1,605.9 1405.7 1523.8 1460.7 Changes in Inventories of Finished Goods and Work in Progress -356.2 -124.5 -139.0 8.0 Gross Profit 2,275.3 2,681.
Slide 34: Summary Statement of Assets and Liabilities
Summary Statement of Assets and Liabilities (in INR mn) Particulars H1 FY22 Mar 21 Particulars H1 FY22 Mar 21 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1,450.87 956.56 (i) Equity share capital 146.37 146.37 (ii) Right to Use Asset 12.86 14.72 (ii) Othe
Slide 35: Summary statement of Cashflow
Summary statement of Cashflow (in INR mn) Particulars H1 FY22 FY21 FY20 FY19 Cash Flow from Operating Activities Profit before Tax 917.0 1673.9 962.3 571.0 Adjustment for Non-Operating Items 38.5 53.1 102.4 124.6 Operating Profit before Working Capital Changes 955.5 1727.0 1064.7 695.6 Changes in Wo
Slide 36: Glossary
Glossary • API – Active Pharmaceutical Intermediates • DMF – Drug Master File • CEP – Certificate of Sustainability • USFDA – US Food And Drug Administration • EDQM – European Directorate for the Quality of Medicines & HealthCare • IDL – Import Drug Licence of China • KFDA – Korea Medical Device Reg
Slide 37: Thank You!
Thank You! Company : Investor Relations Advisors : Orient Capital (a division of Link Group) Supriya Lifescience Limited Mr. Rajesh Agrawal CIN: U51900MH2008PLC180452 +91 99674 91495 Mr. Ashish Nayak – Chief Financial Officer rajesh.agrawal@linkintime.co.in cfo@supriyalifescience.com Ms. Rasika Sawa
Supriya Lifescience — Q3 FY2022 Earnings Presentation on 6ix